van Ginneken Egidia E M, Drooglever-Fortuyn Hal, Smits Paul, Rongen Gerard A
Department of General Internal Medicine, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
J Cardiovasc Pharmacol. 2004 Feb;43(2):276-80. doi: 10.1097/00005344-200402000-00017.
Adenosine is an endogenous purine with vasodilating and cardioprotective properties. Animal experiments have shown that some benzodiazepine-induced effects can be explained by potentiation of adenosine effects, via inhibition of the nucleoside transport system. The objective of this study was to determine whether the frequently used benzodiazepines diazepam and midazolam increase adenosine-induced vasodilation in the human forearm vascular bed, measured by venous occlusion plethysmography. Adenosine (0.6, 6, 20, and 60 nmol/min/dl ForeArm Volume) was infused into the brachial artery with and without concomitant separate infusion of diazepam (21 nmol/min/dl, n = 9) and midazolam (23 nmol/min/dl, n = 8). Plasma concentrations of diazepam resp. midazolam at the end of the infusion protocol averaged 0.5 +/- 0.2 microg/ml plasma (1.6 microM) for diazepam versus 1.2 +/- 0.4 microg/ml plasma (3 microM) for midazolam. Intra-arterial infusion of the benzodiazepines did not alter baseline vascular tone, and had no significant influence on the forearm vasodilator response to adenosine. The adenosine-induced relative change in Forearm Vascular Resistance (FVR) was -3 +/- 7, -48 +/- 8, -75 +/- 6, and -85 +/- 3% in the absence and 3.5 +/- 11, -54 +/- 5, -74 +/- 5, and -82 +/- 3% resp. in the presence of diazepam (P > 0.1, repeated measures ANOVA, n = 9). Likewise, in the absence resp. presence of midazolam, FVR fell by 1 +/- 6, 55 +/- 5, 74 +/- 3, and 84 +/- 2% resp. 11 +/- 11, 59 +/- 2, 80 +/- 3, and 87 +/- 2% (P > 0.1, n = 7). Intra-brachial infusion of diazepam and midazolam resulting in forearm concentrations in the high therapeutic range does not augment adenosine-induced forearm vasodilation. A possible interaction at supra-therapeutic levels of the benzodiazepines can not be excluded from the present study, but lacks clinical significance.
腺苷是一种具有血管舒张和心脏保护特性的内源性嘌呤。动物实验表明,一些苯二氮䓬类药物诱导的效应可以通过抑制核苷转运系统增强腺苷效应来解释。本研究的目的是通过静脉阻塞体积描记法测定常用的苯二氮䓬类药物地西泮和咪达唑仑是否会增强人前臂血管床中腺苷诱导的血管舒张。在肱动脉中分别单独输注和不输注地西泮(21纳摩尔/分钟/分升前臂体积)和咪达唑仑(23纳摩尔/分钟/分升前臂体积)的情况下,将腺苷(0.6、6、20和60纳摩尔/分钟/分升前臂体积)注入肱动脉。输注方案结束时,地西泮和咪达唑仑的血浆浓度分别平均为0.5±0.2微克/毫升血浆(1.6微摩尔)和1.2±0.4微克/毫升血浆(3微摩尔)。动脉内输注苯二氮䓬类药物不会改变基线血管张力,对前臂对腺苷的血管舒张反应也没有显著影响。在不存在地西泮的情况下,腺苷诱导的前臂血管阻力(FVR)相对变化分别为-3±7、-48±8、-75±6和-85±3%,在存在地西泮的情况下分别为3.5±11、-54±5、-74±5和-82±3%(P>0.1,重复测量方差分析,n = 9)。同样,在不存在和存在咪达唑仑的情况下,FVR分别下降1±6、55±5、74±3和84±2%以及11±11、59±2、80±3和87±2%(P>0.1,n = 7)。在前臂中产生高治疗范围浓度的肱内输注地西泮和咪达唑仑不会增强腺苷诱导的前臂血管舒张。本研究不能排除苯二氮䓬类药物超治疗水平时可能存在的相互作用,但缺乏临床意义。